Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.
Abstract
Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.
참고문헌 (15)
- Wang C, "A human monoclonal antibody blocking SARS-CoV-2 infection", Nat Commun, 11, pp.2251~ (2020)
- Yang Y, "SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies", Signal Transduct Target Ther, 6, pp.95~ (2021)
- Kim Sun Bean, "Revised Korean Society of Infectious Diseases", National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19, 2021, pp.53(1), 166~219[DOI]
- Gottlieb RL, "Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial", JAMA, 325, pp.632~644 (2021)
- Chen P, "SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19", N Engl J Med, 384, pp.229~237 (2021)
- Weinreich DM, "REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19", N Engl J Med, 384, pp.238~251 (2021)
- Guyatt G, "GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes", J Clin Epidemiol, 66, pp.151~157 (2013)
- "Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COVTM (casirivimab with imdevimab)"[URL]
- "Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab"[URL]
- "Drug information of regdanvimab"[URL]
- "Clinical spectrum of SARS-CoV-2 infection"[URL]
- "EMA issues advice on use of regdanvimab for treating COVID-19"[URL]
- "Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19"[URL]
- "Regeneron reports positive interim data with REGEN-COV™ antibody cocktail used as passive vaccine to prevent COVID-19"[URL]
- "Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59"[URL]